Longeveron Inc. (LGVN)
Nasdaq · Healthcare · Biotechnology
$2.51−2.71%as of Oct 6, 2026, 1:35 AM ET
- Market cap
- $8.0M
- 52-week range
- $2.30 – $12.30
- 52-week change
- −68.11%
- EPS (trailing)
- −$9.90
- Next earnings
- Nov 4, 2026
Fiscal year to Dec 2025
- Revenue
- $1.2M (−49.87%)
- Net income
- −$22.7M
- Operating margin
- −1942.2%
- Diluted EPS
- −$1.29
- Free cash flow
- −$18.9M
From the company’s annual report on SEC EDGAR.
About Longeveron Inc.
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States. Its lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors which is in phase 3 clinical trial to treat hypoplastic left heart syndrome; completed phase 2a clinical trial to treat Alzheimer's disease, as well as in phase 2b clinical trial to treat aging frailty. The company was incorporated in 2014 and is headquartered in Miami, Florida.
Headquarters: Miami, United States · 38 employees · longeveron.com